-
1
-
-
78649359184
-
Inflammatory breast cancer: the disease, the biology, the treatment
-
Robertson F.M., Bondy M., Yang W., Yamauchi H., Wiggins S., Kamrudin S., Krishnamurthy S., Le-Petross H., Bidaut L., Player A.N., Barsky S.H., Woodward W.A., Buchholz T., Lucci A., Ueno N.T., Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J. Clin. 2010, 60:351-375.
-
(2010)
CA Cancer J. Clin.
, vol.60
, pp. 351-375
-
-
Robertson, F.M.1
Bondy, M.2
Yang, W.3
Yamauchi, H.4
Wiggins, S.5
Kamrudin, S.6
Krishnamurthy, S.7
Le-Petross, H.8
Bidaut, L.9
Player, A.N.10
Barsky, S.H.11
Woodward, W.A.12
Buchholz, T.13
Lucci, A.14
Ueno, N.T.15
Cristofanilli, M.16
-
2
-
-
0034518232
-
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells
-
van Golen K.L., Wu Z.F., Qiao X.T., Bao L., Merajver S.D. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000, 2:418-425.
-
(2000)
Neoplasia
, vol.2
, pp. 418-425
-
-
van Golen, K.L.1
Wu, Z.F.2
Qiao, X.T.3
Bao, L.4
Merajver, S.D.5
-
3
-
-
77950690023
-
Interleukin-6 in bone metastasis and cancer progression
-
Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer 2010, 46:1223-1231.
-
(2010)
Eur. J. Cancer
, vol.46
, pp. 1223-1231
-
-
Ara, T.1
Declerck, Y.A.2
-
4
-
-
0031969898
-
Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer
-
De Vita F., Orditura M., Auriemma A., Infusino S., Roscigno A., Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol. Rep. 1998, 5:649-652.
-
(1998)
Oncol. Rep.
, vol.5
, pp. 649-652
-
-
De Vita, F.1
Orditura, M.2
Auriemma, A.3
Infusino, S.4
Roscigno, A.5
Catalano, G.6
-
5
-
-
0033036097
-
Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
-
Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999, 19:1427-1432.
-
(1999)
Anticancer Res.
, vol.19
, pp. 1427-1432
-
-
Zhang, G.J.1
Adachi, I.2
-
6
-
-
77649239393
-
Serum interleukin-6 levels in colorectal cancer patients - a summary of published results
-
Knupfer H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients - a summary of published results. Int. J. Colorectal Dis. 2010, 25:135-140.
-
(2010)
Int. J. Colorectal Dis.
, vol.25
, pp. 135-140
-
-
Knupfer, H.1
Preiss, R.2
-
7
-
-
79960182099
-
Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (Sirukumab) in healthy subjects in a first-in-human study
-
Xu Z., Bouman-Thio E., Comisar C., Frederick B., Van Hartingsveldt B., Marini J.C., Davis H.M., Zhou H. Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (Sirukumab) in healthy subjects in a first-in-human study. Br. J. Clin. Pharmacol. 2011.
-
(2011)
Br. J. Clin. Pharmacol.
-
-
Xu, Z.1
Bouman-Thio, E.2
Comisar, C.3
Frederick, B.4
Van Hartingsveldt, B.5
Marini, J.C.6
Davis, H.M.7
Zhou, H.8
-
8
-
-
0142250392
-
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence
-
Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 4653-4665
-
-
Trikha, M.1
Corringham, R.2
Klein, B.3
Rossi, J.F.4
-
9
-
-
28644436100
-
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
-
Silverman J., Liu Q., Bakker A., To W., Duguay A., Alba B.M., Smith R., Rivas A., Li P., Le H., Whitehorn E., Moore K.W., Swimmer C., Perlroth V., Vogt M., Kolkman J., Stemmer W.P. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 2005, 23:1556-1561.
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 1556-1561
-
-
Silverman, J.1
Liu, Q.2
Bakker, A.3
To, W.4
Duguay, A.5
Alba, B.M.6
Smith, R.7
Rivas, A.8
Li, P.9
Le, H.10
Whitehorn, E.11
Moore, K.W.12
Swimmer, C.13
Perlroth, V.14
Vogt, M.15
Kolkman, J.16
Stemmer, W.P.17
-
10
-
-
1542719614
-
Hemoadsorption removes tumor necrosis factor, interleukin-6, interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia
-
Kellum J.A., Song M., Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit. Care Med. 2004, 32:801-805.
-
(2004)
Crit. Care Med.
, vol.32
, pp. 801-805
-
-
Kellum, J.A.1
Song, M.2
Venkataraman, R.3
-
11
-
-
33644759333
-
Targeting effective blood pressure control with angiotensin receptor blockers
-
Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. Int. J. Clin. Pract. 2006, 60:315-320.
-
(2006)
Int. J. Clin. Pract.
, vol.60
, pp. 315-320
-
-
Asmar, R.1
-
12
-
-
67749084409
-
The clinical efficacy of tocilizumab in rheumatoid arthritis
-
Mircic M., Kavanaugh A. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc) 2009, 45:189-197.
-
(2009)
Drugs Today (Barc)
, vol.45
, pp. 189-197
-
-
Mircic, M.1
Kavanaugh, A.2
-
13
-
-
53249090648
-
Protein kinase CK2 in human diseases
-
Guerra B., Issinger O.G. Protein kinase CK2 in human diseases. Curr. Med. Chem. 2008, 15:1870-1886.
-
(2008)
Curr. Med. Chem.
, vol.15
, pp. 1870-1886
-
-
Guerra, B.1
Issinger, O.G.2
-
14
-
-
75349084777
-
Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
-
Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?. Biochim. Biophys. Acta 2010, 1804:499-504.
-
(2010)
Biochim. Biophys. Acta
, vol.1804
, pp. 499-504
-
-
Ruzzene, M.1
Pinna, L.A.2
-
15
-
-
34447345994
-
The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling
-
Parhar K., Morse J., Salh B. The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int. J. Colorectal Dis. 2007, 22:601-609.
-
(2007)
Int. J. Colorectal Dis.
, vol.22
, pp. 601-609
-
-
Parhar, K.1
Morse, J.2
Salh, B.3
-
16
-
-
27744470520
-
Role for casein kinase 2 in the regulation of HIF-1 activity
-
Mottet D., Ruys S.P., Demazy C., Raes M., Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int. J. Cancer 2005, 117:764-774.
-
(2005)
Int. J. Cancer
, vol.117
, pp. 764-774
-
-
Mottet, D.1
Ruys, S.P.2
Demazy, C.3
Raes, M.4
Michiels, C.5
-
17
-
-
78650321320
-
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy
-
Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O'Brien S.E., Bliesath J., Omori M., Huser N., Ho C., Proffitt C., Schwaebe M.K., Ryckman D.M., Rice W.G., Anderes K. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010, 70:10288-10298.
-
(2010)
Cancer Res.
, vol.70
, pp. 10288-10298
-
-
Siddiqui-Jain, A.1
Drygin, D.2
Streiner, N.3
Chua, P.4
Pierre, F.5
O'Brien, S.E.6
Bliesath, J.7
Omori, M.8
Huser, N.9
Ho, C.10
Proffitt, C.11
Schwaebe, M.K.12
Ryckman, D.M.13
Rice, W.G.14
Anderes, K.15
-
18
-
-
78751668859
-
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer
-
Pierre F., Chua P.C., O'Brien S.E., Siddiqui-Jain A., Bourbon P., Haddach M., Michaux J., Nagasawa J., Schwaebe M.K., Stefan E., Vialettes A., Whitten J.P., Chen T.K., Darjania L., Stansfield R., Anderes K., Bliesath J., Drygin D., Ho C., Omori M., Proffitt C., Streiner N., Trent K., Rice W.G., Ryckman D.M. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J. Med. Chem. 2010, 54:635-654.
-
(2010)
J. Med. Chem.
, vol.54
, pp. 635-654
-
-
Pierre, F.1
Chua, P.C.2
O'Brien, S.E.3
Siddiqui-Jain, A.4
Bourbon, P.5
Haddach, M.6
Michaux, J.7
Nagasawa, J.8
Schwaebe, M.K.9
Stefan, E.10
Vialettes, A.11
Whitten, J.P.12
Chen, T.K.13
Darjania, L.14
Stansfield, R.15
Anderes, K.16
Bliesath, J.17
Drygin, D.18
Ho, C.19
Omori, M.20
Proffitt, C.21
Streiner, N.22
Trent, K.23
Rice, W.G.24
Ryckman, D.M.25
more..
-
19
-
-
26844578050
-
In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line
-
Hoffmeyer M.R., Wall K.M., Dharmawardhane S.F. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell. Int. 2005, 5:11.
-
(2005)
Cancer Cell. Int.
, vol.5
, pp. 11
-
-
Hoffmeyer, M.R.1
Wall, K.M.2
Dharmawardhane, S.F.3
-
20
-
-
0031432550
-
IL-6-regulated transcription factors
-
Akira S. IL-6-regulated transcription factors. Int. J. Biochem. Cell Biol. 1997, 29:1401-1418.
-
(1997)
Int. J. Biochem. Cell Biol.
, vol.29
, pp. 1401-1418
-
-
Akira, S.1
-
21
-
-
77952687319
-
Novel targeted therapies in inflammatory breast cancer
-
Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. Cancer 2011, 116:2837-2839.
-
(2011)
Cancer
, vol.116
, pp. 2837-2839
-
-
Cristofanilli, M.1
-
22
-
-
0029959753
-
Pyrrolidine dithiocarbamate inhibits the production of interleukin-6 interleukin-8 and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity
-
Munoz C., Pascual-Salcedo D., Castellanos M.C., Alfranca A., Aragones J., Vara A., Redondo J.M., de Landazuri M.O. Pyrrolidine dithiocarbamate inhibits the production of interleukin-6 interleukin-8 and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity. Blood 1996, 88:3482-3490.
-
(1996)
Blood
, vol.88
, pp. 3482-3490
-
-
Munoz, C.1
Pascual-Salcedo, D.2
Castellanos, M.C.3
Alfranca, A.4
Aragones, J.5
Vara, A.6
Redondo, J.M.7
de Landazuri, M.O.8
-
23
-
-
36849012237
-
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
-
Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., Bromberg J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 2007, 117:3846-3856.
-
(2007)
J. Clin. Invest.
, vol.117
, pp. 3846-3856
-
-
Gao, S.P.1
Mark, K.G.2
Leslie, K.3
Pao, W.4
Motoi, N.5
Gerald, W.L.6
Travis, W.D.7
Bornmann, W.8
Veach, D.9
Clarkson, B.10
Bromberg, J.F.11
-
24
-
-
70449657727
-
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin
-
Ji H., Wang J., Nika H., Hawke D., Keezer S., Ge Q., Fang B., Fang X., Fang D., Litchfield D.W., Aldape K., Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol. Cell. 2009, 36:547-559.
-
(2009)
Mol. Cell.
, vol.36
, pp. 547-559
-
-
Ji, H.1
Wang, J.2
Nika, H.3
Hawke, D.4
Keezer, S.5
Ge, Q.6
Fang, B.7
Fang, X.8
Fang, D.9
Litchfield, D.W.10
Aldape, K.11
Lu, Z.12
-
25
-
-
0037112514
-
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells
-
Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., Sonenshein G.E. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002, 62:6770-6778.
-
(2002)
Cancer Res.
, vol.62
, pp. 6770-6778
-
-
Romieu-Mourez, R.1
Landesman-Bollag, E.2
Seldin, D.C.3
Sonenshein, G.E.4
-
26
-
-
33748163052
-
Multiple myeloma cell survival relies on high activity of protein kinase CK2
-
Piazza F.A., Ruzzene M., Gurrieri C., Montini B., Bonanni L., Chioetto G., Di Maira G., Barbon F., Cabrelle A., Zambello R., Adami F., Trentin L., Pinna L.A., Semenzato G. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006, 108:1698-1707.
-
(2006)
Blood
, vol.108
, pp. 1698-1707
-
-
Piazza, F.A.1
Ruzzene, M.2
Gurrieri, C.3
Montini, B.4
Bonanni, L.5
Chioetto, G.6
Di Maira, G.7
Barbon, F.8
Cabrelle, A.9
Zambello, R.10
Adami, F.11
Trentin, L.12
Pinna, L.A.13
Semenzato, G.14
|